Background/Objectives: In vitro and animal studies have reported that young broccoli sprouts improve oxidative stress status in diabetic condition. The objective of this double-blind, placebo-controlled, randomized clinical trial was to investigate the effects of broccoli sprouts powder (BSP) on some oxidative stress parameters in type 2 diabetes patients. Subjects/Methods: A total of 81 patients with type 2 diabetes were randomly assigned to one of three treatment groups for 4 weeks. The groups received either 10 g/d BSP (n ¼ 27), 5 g/d BSP (n ¼ 29) or placebo (n ¼ 25). Serum total antioxidant capacity (TAC), total oxidant status (TOS), oxidative stress index (OSI), malondialdehyde (MDA) and oxidized low density lipoprotein (LDL) cholesterol were measured at baseline and at 4 weeks after treatment. Results: In all, 63 patients in three groups were included in the analysis: 10 g/d BSP (n ¼ 21), 5 g/d (n ¼ 22) and placebo (n ¼ 20). After 4 weeks, consumption of BSP resulted in significant decrease in MDA (P ¼ 0.001 for treatment effect), oxidized low density lipoprotein cholesterol (P ¼ 0.03 for treatment effect), OSI (P ¼ 0.001 for treatment effect) and significant increase in TAC (P ¼ 0.001 for treatment effect). No effects were found on TOS. Conclusion: BSP had favorable effects on oxidative stress status in type 2 diabetes patients.
Introduction
Type 2 diabetes is associated with oxidative stress due to abnormal metabolism of glucose and lipids (Evans et al., 2002; Goycheva et al., 2004) . Increased generation of free radicals and depletion of antioxidant capacity in diabetic conditions induces imbalance of oxidant/antioxidant status (Opara et al., 1999; Valko et al., 2007) , events which may lead to long term vascular complications, disability and death in diabetes patients (Bekyarova et al., 2007; Son, 2007) . Inhibition of these oxidative processes could prevent the onset and the development of long-term diabetic complications (Whiteside, 2005; Pérez-Matute et al., 2009) . Dietary supplementation with antioxidant phytochemicals may be a successful strategy to decrease this risk of pathological complications (Jurlink, 2001; Dembinska-Kiec et al., 2008) .
Broccoli sprouts is a good source of health promoting compounds (Carvajal et al., 2006; Jeffery and Araya, 2009) . A key bioactive component in broccoli sprouts is sulforaphane (SFN; 1-isothiocyanate-4-methylsulfinylbutane) (Keum et al., 2004; Verkerk et al., 2009) , which is the most potent phase-2 protein inducer found in food sources as one arm of the endogenous antioxidant defense (Fahey and Talalay, 1999; Dinkova-Kostova et al., 2007; Angeloni et al., 2009; Riedl et al., 2009) . In vitro studies demonstrate that SFN reduces oxidative stress through the activation of antioxidant response pathways (Piao et al., 2005; Xue et al., 2008; Zhu et al., 2008) . Animal studies have reported that supplementation with broccoli sprouts, containing SFN, resulted in attenuation of oxidative stress and inflammation (Wu et al., 2004; Cho et al., 2006) . In addition, oral administration of broccoli extract in diabetic rats led to significant decrease in oxidative stress through the inhibition of lipid peroxidation (Piao et al., 2005) . Recently, a phase-1 study revealed that intake of fresh broccoli sprouts for 1 week improved some biomarkers of oxidative stress in healthy human, (Murashima et al., 2004) , whereas the effects of broccoli sprouts in diabetes patients has not yet been determined. We, therefore, conducted this trial to investigate the effect of broccoli sprouts powder (BSP) on some biomarkers of oxidative stress in type 2 diabetes patients.
Patients and methods
Patients and study design This was a parallel, randomized, double-blind and placebocontrolled study. Type 2 diabetes patients, aged 18-60 years, with a clinical diagnosis of type 2 diabetes for at least 1 year, were recruited from the Iran Diabetes Society and the endocrine clinic of Taleghani Medical Center (Tehran, Iran). Patients were excluded from the trial if they had severe impairment of cardiac, hepatic or renal function, gestation or lactation and if they used insulin injection or consumed estrogen, vitamin K-antagonists or antioxidant supplements. A total of 81 patients, initially eligible, were included in the study. Subjects were randomly assigned to one of three groups: group A (BSP 10 g/d, n ¼ 27), group B (BSP 5 g/d, n ¼ 29) and group C (placebo, n ¼ 25). Random allocation of patients to treatment groups was performed by sequentially numbered containers. Randomization was performed by an assistant and the group allocation was blinded for the investigator and participants. Dietary recalls for 3 days, including 2 weekdays and 1 weekend day, was collected at baseline, and again after 4 weeks from subjects, to monitor dietary compliance and assess nutrient intakes. Weight was measured with digital scale (Seca 707, Hamburg, Germany) and body mass index was calculated at baseline and 4 weeks later.
Ethics approval for the trial was obtained from ethical committee of the Research Institute for Endocrine Sciences of the Shahid Beheshti University of Medical Sciences (Tehran, Iran). This clinical trial has been registered in the Iranian Registry of Clinical Trials at http://www.irct.ir with the following identification: IRCT138901181640N2, and was conducted between March and July 2010. The results are reported according to Consolidated Standards of Reporting Trials guidelines (Schulz et al., 2010) .
Interventions BSP standardized for SFN (BroccoPhane), was purchased from Cyvex Nutrition Company (Irvine, CA, USA). The SFN content of BSP was determined B22.5 mmol/g by the manufacturer, by high performance liquid chromatography method. At baseline, subjects received 28 packets containing either 5 or 10 g of BSP in BSP groups, whereas controls were given 5 g cornstarch powder colored with chlorophyll. Packets were identically packaged to be indistinguishable. Patients were recommended to consume one packet daily for 4 weeks, preferably with a beverage after meals to reduce gastrointestinal complications, also they were asked to maintain their regular diet and lifestyle, during the study period. Patients were contacted every week to evaluate compliance to intervention and inquire regarding possible side effects. Patients were excluded from the analysis if they consumed o80% of the packets, or had changed their medication, or reported severe side effects.
Outcome measurements
Fasting venous blood samples were taken after 12-14 h overnight fast, at baseline and again 4 weeks after intervention. Serum was separated and frozen at À70 1C, for biochemical analysis on the day of blood collection. Oxidant/antioxidant status was evaluated by assaying total oxidant status (TOS), total antioxidant capacity (TAC) and oxidative stress index (OSI). Lipid peroxidation was evaluated by assaying serum malondialdehyde (MDA) and oxidized-low density lipoprotein (OX-LDL).
Biochemical analysis
Serum MDA was measured spectrophotometrically by the thiobarbituric acid (TBARS) assay kit (Cayman Chemical Inc., Ann Arbor, MI, USA). The monoclonal antibody was used to quantify the concentration of serum OX-LDL using the ELISA kit (Mercodia Company, Uppsala, Sweden). Serum TAC was measured spectrophotometrically by the antioxidant assay kit (Cayman Chemical Inc.), which relies on the ability of serum antioxidants to inhibit the oxidation of ABTS (2,2 0 -azino-di-(3-ethylbenzthiazoline sulfonate)) to ABTS þ by metmyoglobin.
The capacity of the antioxidants to prevent ABTS oxidation is compared with that of Trolox, a water-soluble tocopherol analog, and is quantified as molar Trolox equivalents (Erel, 2004a, b) . Serum TOS was measured spectrophotometrically by the total oxidant assay kit (Rel Assay Company, Gaziantep, Turkey). The assay relies on the ability of serum oxidants to oxidize the ferrous ion-chelator complex to ferric ion and the results are expressed in terms of molar hydrogen peroxide equivalents (Erel, 2004a, b) . Oxidative stress index, a new indicator parameter of oxidative stress level, was calculated using the formula (Aslan et al., 2007; Rabus et al., 2008; Cumurcu et al., 2009) 
The intra assay coefficients of variation of all assays were o5%.
Sample size estimation and statistical methods
The sample size was designed to detect a difference among groups in serum TAC with 95% confidence interval and 90% power.
Statistical analysis was performed with SPSS (version 16.0; SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was used to test for a normal distribution. Differences between the three groups at baseline were tested with one-way analysis of variance. Student's paired t-test was used to compare baseline and 4-week values in each group. The effects of the BSP were compared by analysis of covariance with 4-week values as dependent variables, baseline values as covariates and treatment group as a fixed factor. When the analysis indicated a significant effect of BSP, the groups were compared pairwise by the Bonferroni's test. P-value o0.05 was considered significant.
Results
In all, 63 patients (10 g/d BSP (n ¼ 21), 5 g/d (n ¼ 22), placebo (n ¼ 20)) were included in the analysis as presented in the flow chart (Figure 1) . No significant differences between groups were seen for age, sex, weight, body mass index, duration of diabetes and antidiabetic drugs. There were no significant differences in the clinical and biological variables measured between the patients in the three treatment groups at baseline (Table 1 ). On the basis of self-reports, the subject's lifestyle was unchanged throughout the study. There was no significant difference between the groups in total energy and nutrients intake, as estimated by the 3-day dietary recalls. No serious adverse events or side effects were reported. Mild gastrointestinal events, including flatulence (n ¼ 5) and increased defecation (n ¼ 1) were reported.
The effects of BSP on oxidative stress parameters are presented in Table 2 ; BSP treatment resulted in significant decrease in MDA (Po0.001 for treatment effect), OX-LDL (Po0.05 for treatment effect), OSI (Po0.001 for treatment effect) and significant increase in TAC (Po0.001 for treatment effect). No effects were found on TOS. Mean differences in oxidative stress parameters compared with baseline values, are presented in Figure 2 . There were 9 and 5% significant decreases in serum MDA and oxidized LDL in group A only (Po0.05). There were 16 and 10% significant increases in serum TAC and 14 and 9% decrease in oxidative stress indices in group A and B, respectively, after 4 weeks intervention. Also, there were significant decrease in fasting blood glucose (FBS) in BSP groups (19.6±16.4 and 12.0±18.3%, in group A and B, respectively, Po0.01), and non-significant decrease in controls (3.8 ± 41.0%, P ¼ 0.25). There was no significant difference in mean FBS in the fourth week, between three groups (Table 2) .
Discussion
The present study demonstrated that broccoli sprouts improved oxidant/antioxidant status in diabetes patients through increase in TAC and non-significant decrease in (n=1) Analyzed (n=20) Analyzed (n=22) Analyzed (n=21) Figure 1 Flow chart of the study.
Broccoli sprouts and oxidative status Z Bahadoran et al serum reactive oxygen metabolites. Administration of BSP at doses of 10 g/d for 4 weeks induced improvement in lipid peroxidation in type 2 diabetes patients. These effects were seen with a decrease in plasma MDA and OX-LDL. Increased lipid peroxidation in diabetes has been indicated as an important factor in the pathogenesis of complications (Altomare et al., 1992; Memis¸ogullari and Bakan, 2004; Likidlilid et al., 2010) . Recent studies have indicated that the antioxidant supplement has important antagonizing effects on lipid peroxidation in patients with type 2 diabetes and might be beneficial in preventing cardiovascular complications (Chisolm and Steinberg, 2000; Stranges et al., 2008; Nakhjavani et al., 2010) . In one study, administration of 100 g/d fresh broccoli sprouts in healthy subjects reduced urinary 8-isoprostane and plasma phosphatidylcholine hydroperoxide and increased CoQ 10 H2 (reduced form of coenzyme Q 10 )/coenzyme Q 10 ratio as an effective inhibitor of oxidative damage in LDL (Menke et al., 2004; Murashima et al., 2004) . In addition, oral administration of 100 or 200 mg/kg broccoli extract in diabetic rats resulted in significant reduction in serum thiobarbituric acid-reactive substances (Cho et al., 2006) . Administration of 200 mg/d dried broccoli sprouts in rats decreased oxidative stress as shown by increased glutathione as a critical antioxidant for scavenging peroxides and other lipid derived oxidant (Wu and Juurlink, 2001; Wu et al., 2004) . In the present study, there were no significant changes in lifestyle, dietary intake or medication of the subjects throughout the study duration; hence, any changes in variables were probably a result of the BSP treatment. The Figure 2 Mean ± s.d. differences in oxidative stress parameters compared with baseline values, in groups (*significant difference within the groups using paired t-test, Po0.001). MDA, malodialdehyde; OX-LDL, oxidized low density lipoprotein; TAC, total antioxidant capacity; TOS, total oxidant status; OSI, oxidative stress index.
Broccoli sprouts and oxidative status Z Bahadoran et al beneficial effects of broccoli sprouts on oxidative stress, observed in this study, could be due to the high SFN content of BSP. In vitro animal and human studies, have reported the beneficial biological effects of SFN through induction of important cellular antioxidants and phase 2 enzymes, including superoxide dismutase, catalase, NAD(P)H:quinine oxidoreductase 1, glutathione, glutathione peroxidase, glutathione reductase and glutathione-s-transferase (Thimmulappa et al., 2002; Ping et al., 2010) . An important action of phase 2 proteins, mainly enzymes, is inactivation of oxidants (Cao et al., 2003) .
In this study, the FBS was not the primary endpoint; however, it significantly decreased in both BSP groups. Given concern about possible effects of 5 g/d corn starch on glycemic control, there was no significant change in FBS in controls during intervention. Longer periods of intervention and measurement of glycated hemoglobin are recommended to confirm the effect of broccoli sprouts on FBS.
The ideal dose of broccoli sprouts has not yet been determined. The doses used in this study provided 225 mmol and 112 mmol SFN isothiocyanates daily per 10 g and 5 g BSP doses, respectively. Effects on lipid peroxidation parameters were seen only with the higher dose, although positive effects on TAC were seen with both doses. Effects of broccoli sprouts administration on phase 2 enzymes expression in the human airway, have only been observed at doses 451 mmol SFN with a significant dose-response effect in phase 2 enzymes expression (Riedl et al., 2009) .
In this study, we observed mild gastrointestinal events, mainly flatulence through administration of broccoli sprouts. Previously, Riedl et al., (2009) reported that administration of 200 g/d broccoli sprouts homogenates in healthy subjects, resulted in flatulence.
The present study does have a few limitations, study duration was 4 weeks and only one sample was obtained following intervention. Our doses were limited and, therefore, dose-response analysis and determination of an optimum dose were not possible.
To conclude in the present study, administration of BSP for 4 weeks in type 2 diabetes patients decreased serum MDA and OX-LDL concentrations and increased TAC, which may be useful to improve oxidant/antioxidant status in such patients. Further studies with longer duration and different doses are needed to confirm the effects of broccoli sprouts and related mechanisms.
